| COVID-19 |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.98 |
| Electronic Medical Record |
0 |
0.37 |
| Electronic Health Record (EHR) |
0 |
0.36 |
| Healthcare and Medical Technology |
0 |
0.3 |
| Artificial Intelligence |
0 |
0.25 |
| Clinical Research |
0 |
0.12 |
| DPP-4 Inhibitors |
0 |
0.12 |
| Expert Testimony |
0 |
0.12 |
| Grant |
0 |
0.12 |
| Minnesota |
0 |
0.12 |
| Pharmacoepidemiology |
0 |
0.12 |
| Receptors |
0 |
0.12 |
| Salary and Compensation |
0 |
0.12 |
| SGLT2 Inhibitor |
0 |
0.12 |
| Sulfonylureas |
0 |
0.12 |
| Revenue and Practice Management |
0 |
0.1 |